Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.

Abstract

BACKGROUND:

Micafungin is a well-tolerated and effective prophylactic antifungal agent used in hematologic diseases. In this prospective trial, we evaluated the efficacy and safety of prophylactic micafungin during first induction chemotherapy in patients with acute leukemia. We also compared outcomes of prophylactic micafungin with those of prophylactic posaconazole in acute myeloid leukemia (AML).

METHODS:

Medically fit patients with newly diagnosed acute leukemia received 50 mg micafungin intravenously once daily from the initiation of first induction chemotherapy to recovery of neutrophil count, suspected fungal infection, or unacceptable drug-related toxicity ( Clinicaltrials.gov number, NCT02440178). The primary end point was incidence of invasive fungal infection, and the secondary end points were adverse events of prophylactic micafungin and mortality during induction therapy.

RESULTS:

The 65 patients (median age = 51 years, male:female = 34:31) enrolled in this study had diagnoses of AML (33, 50.8%), acute lymphoblastic leukemia (31, 47.7%), and acute biphenotypic leukemia (1, 1.5%). Median duration of micafungin treatment was 24 days (range 1-68), with proven invasive fungal disease in one patient (1.5%) and possible fungal infection in two patients (3.1%). Three of the patients (4.6%) experienced the following adverse events, but all events were tolerable: liver function abnormality (Grade 2, n = 1; Grade 3, n = 1) and allergic reaction (Grade 2, n = 1). Three patients died during induction therapy, and invasive aspergillosis pneumonia was the cause of death for one of those patients. Overall, 19 patients (29.2%) discontinued prophylactic micafungin, and 18 (27.7%) patients switched to another antifungal agent. We observed no fungal infections caused by amphotericin B-resistant organisms. In AML patients, outcomes of prophylactic micafungin during induction chemotherapy did not differ significantly with those of prophylactic posaconazole with regard to incidence of fungal infections, rate of discontinuation, or safety.

CONCLUSIONS:

Our study demonstrates that prophylactic micafungin is safe and effective in patients with acute leukemia undergoing induction chemotherapy. Outcomes in patients with AML were similar to those of prophylactic posaconazole, indicating the usefulness of micafungin as a prophylactic antifungal agent during induction chemotherapy for AML.

TRIAL REGISTRATION:

Clinicaltrials.gov NCT02440178, registered May 12th 2015.

• Authors: Hyunkyung Park, Jeonghwan Youk, Dong-Yeop Shin, Junshik Hong, Inho Kim, Nam Joong Kim, Jeong-Ok Lee, Soo-Mee Bang, Sung-Soo Yoon, Wan Beom Park, Youngil Koh
• Journal: BMC cancer (BMC Cancer) Vol. 19 Issue 1 Pg. 358 (Apr 16 2019) ISSN: 1471-2407 [Electronic] England
• PMID: 30991992 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Micafungin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antifungal Agents (therapeutic use)
• Female
• Humans
• Induction Chemotherapy (adverse effects, methods)
• Kaplan-Meier Estimate
• Leukemia, Myeloid, Acute (complications, drug therapy, mortality)
• Male
• Micafungin (therapeutic use)
• Middle Aged
• Mycoses (diagnosis, etiology, prevention & control)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (complications, drug therapy, mortality)
• Prognosis
• Treatment Outcome
• Young Adult